No association between opioids, breast cancer recurrence
the ONA take:
There is no clinically relevant evidence of an association between opioid prescriptions and breast cancer recurrence, a new study published online ahead of print in the journal Cancer has shown.
Because opioids may affect immune function, researchers sought to determine whether postdiagnosis opioid use is associated with breast cancer recurrence. For the retrospective analysis, researchers identified 34,188 patients with incident, early stage breast cancer who were diagnosed between 1996 and 2008 in Denmark.
Results showed that there was no association between ever-use of opioids and breast cancer recurrence. When researchers adjusted for opioid type, strength, duration of use, and cumulative dose, there was still no association.
Researchers found that breast cancer recurrence rates were lower among users of strongly immunosuppressive opioids, but they note that bias could have been a contributing factor.
The findings suggest that opioids, which are frequently use to manage painassociated with comorbid conditions during cancer survivorship, do not increase the risk for developing breast cancer recurrence.
There is no clinically relevant evidence of an association between opioid prescriptions and breast cancer recurrence.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|